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Immunofluorescence staining of squamous cell carcinoma tumor 
isolated from conditional knockout α-catenin mice with anti-
integrin β4 (green) and anti-YAP1 (red) antibodies. The staining 
shows mislocalization of integrin β4 and activation of YAP1 in 
these tumors. 
 





Most human cancers such as breast, colon and skin cancers are carcinomas, meaning that they 
originate in epithelial cells. Epithelial cells line our body surfaces, including our skin, and thus are 
major constituents of our organs. Protein complexes known as adherens junctions (AJs) play an 
important role in the organization of epithelial cells in tissues. AJs not only keep epithelial cells 
together, but also play critical roles in cell-cell signaling during both normal development and cancer. 
αE-catenin, a key component of AJs, is frequently inactivated in human skin squamous cell 
carcinomas (SCC), and it was shown to be a bona fide tumor suppressor using mouse models. 
Previous studies from Dr. Valeri Vasioukhin’s Laboratory (Human Biology Division) identified the 
transcriptional co-activator and oncogene YAP1 as being essential for both hyperproliferation and 
loss of contact inhibition observed in mouse keratinocytes (skin cells) that lacked αE-catenin (αE-
catenin-/-). However, it remains unclear mechanistically how αE-catenin is linked to YAP1 activity. In 
the current Fred Hutch study published in Genes & Development, Dr. Vasioukhin’s Lab uncovered 
that the first known human oncogene and tyrosine kinase SRC, phosphorylates YAP1 in its 
transcription activation domain, and that this phosphorylation is important for YAP1’s transcriptional 
and oncogenic activity. 
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The authors began by extending their previous short interfering RNA screen, which revealed that in 
addition to Yap1, Itgb4 and Src were also required for hyperproliferation of αE-catenin-/- 
keratinocytes. Itgb4 and Src genes encode β4 integrin and the oncoprotein SRC, respectively. The 
researchers found that β4 integrin drives hyperactivation of SRC which is necessary for 
hyperproliferation of αE-catenin-/- keratinocytes. Importantly, SRC was found to promote nuclear 
localization and transcriptional activity of YAP1 independent of the Hippo pathway, the major known 
regulator of YAP1 nuclear accumulation and activity. The investigators showed strong cooperation 
between SRC and YAP1 in malignant transformation. Using phospho-specific antibodies and an in 
vitro kinase assay, the scientists demonstrated that SRC directly phosphorylates YAP1 at three 
tyrosine residues (Y341, Y357, Y394). YAP1 protein replacement experiments utilizing either wild-
type of phosphorylation site mutant YAP1 revealed critical role of SRC-mediated phosphorylation for 
both YAP1- and SRC-mediated cellular transformation. Finally, the researchers leveraged a SCC 
mouse model to demonstrate the potential utility of using an inhibitor of SRC-family kinases, 
dasatinib, for the treatment of SCC tumors that do not express αE-catenin.  
In summary, this study revealed a previously unknown link between an oncogenic tyrosine kinase, 
SRC, and the key effector of the Hippo pathway, YAP1 that warrants further preclinical studies of 
dasatibib in αE-catenin-deficient SCCs. Said Dr. Vasioukhin "Oncogenic tyrosine kinases play an 
important role in human cancer. It is well known that they primarily impact PI3K and 
MAPK pathways. Our studies revealed a direct connection between oncogenic tyrosine kinase 
signaling and the effector of Hippo pathway YAP1. We found that YAP1 is directly phosphorylated at 
three sites by activated SRC family kinases and this phosphorylation results in YAP1 activation and 
malignant transformation. We propose that in addition to PI3K/MAPK, YAP1 phosphorylation and 
activation is another critical downstream pathway required for malignant transformation by 
oncogenic tyrosine kinases". 
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